FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095482600> ?p ?o ?g. }

• W2095482600 endingPage "13" @default.
• W2095482600 startingPage "13" @default.
• W2095482600 abstract "A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins Joohi Jimenez-ShahedDepartment of Neurology, Baylor College of Medicine, Houston, TX, USAAbstract: Dystonia is a movement disorder of uncertain pathogenesis that is characterized by involuntary and inappropriate muscle contractions which cause sustained abnormal postures and movements of multiple or single (focal) body regions. The most common focal dystonias are cervical dystonia (CD) and blepharospasm (BSP). The first-line recommended treatment for CD and BSP is injection with botulinum toxin (BoNT), of which two serotypes are available: BoNT type A (BoNT/A) and BoNT type B (BoNT/B). Conventional BoNT formulations include inactive complexing proteins, which may increase the risk for antigenicity, possibly leading to treatment failure. IncobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a BoNT/A agent that has been recently Food and Drug Administration-approved for the treatment of adults with CD and adults with BSP previously treated with onabotulinumtoxinA (Botox®; Allergen, Inc, Irvine, CA) – a conventional BoNT/A. IncobotulinumtoxinA is the only BoNT product that is free of complexing proteins. The necessity of complexing proteins for the effectiveness of botulinum toxin treatment has been challenged by preclinical and clinical studies with incobotulinumtoxinA. These studies have also suggested that incobotulinumtoxinA is associated with a lower risk for stimulating antibody formation than onabotulinumtoxinA. In phase 3 noninferiority trials, incobotulinumtoxinA demonstrated significant improvements in CD and BSP symptoms in both primary and secondary measures, compared with baseline, and met criteria for noninferiority versus onabotulinumtoxinA. In placebo-controlled trials, incobotulinumtoxinA also significantly improved the symptoms of CD and BSP, with robust outcomes in both primary and secondary measures. The use of incobotulinumtoxinA has been well tolerated in all trials, with an adverse event profile similar to that of onabotulinumtoxinA. Based on these data, incobotulinumtoxinA is a safe and effective BoNT/A for the treatment of CD and BSP, and may pose a lower risk for immunogenicity leading to treatment failure compared with other available BoNT agents. This paper reviews the treatment of focal dystonias with BoNTs, in particular, incobotulinumtoxinA. Controlled trials from the existing incobotulinumtoxinA literature are summarized.Keywords: blepharospasm, botulinum toxin, cervical dystonia, complexing proteins, dystonia, incobotulinumtoxinA (Xeomin®)" @default.
• W2095482600 created "2016-06-24" @default.
• W2095482600 creator A5015721522 @default.
• W2095482600 date "2011-12-01" @default.
• W2095482600 modified "2023-09-27" @default.
• W2095482600 title "A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins" @default.
• W2095482600 cites W114238110 @default.
• W2095482600 cites W1543701391 @default.
• W2095482600 cites W164984803 @default.
• W2095482600 cites W1674686464 @default.
• W2095482600 cites W1716112521 @default.
• W2095482600 cites W1759471442 @default.
• W2095482600 cites W1760472848 @default.
• W2095482600 cites W1811666348 @default.
• W2095482600 cites W1840523915 @default.
• W2095482600 cites W1970669888 @default.
• W2095482600 cites W1971430009 @default.
• W2095482600 cites W1971628366 @default.
• W2095482600 cites W1972838299 @default.
• W2095482600 cites W1975138882 @default.
• W2095482600 cites W1976476391 @default.
• W2095482600 cites W1980333437 @default.
• W2095482600 cites W1981069875 @default.
• W2095482600 cites W1982050085 @default.
• W2095482600 cites W1988172507 @default.
• W2095482600 cites W1990353610 @default.
• W2095482600 cites W1990410007 @default.
• W2095482600 cites W1992969445 @default.
• W2095482600 cites W1997891927 @default.
• W2095482600 cites W1997898720 @default.
• W2095482600 cites W1998446330 @default.
• W2095482600 cites W1999838039 @default.
• W2095482600 cites W2000047663 @default.
• W2095482600 cites W2001900063 @default.
• W2095482600 cites W2004919730 @default.
• W2095482600 cites W2007776037 @default.
• W2095482600 cites W2009941932 @default.
• W2095482600 cites W2015142589 @default.
• W2095482600 cites W2016347261 @default.
• W2095482600 cites W2016750344 @default.
• W2095482600 cites W2016796154 @default.
• W2095482600 cites W2020077121 @default.
• W2095482600 cites W2027089542 @default.
• W2095482600 cites W2027142476 @default.
• W2095482600 cites W2027882596 @default.
• W2095482600 cites W2028448088 @default.
• W2095482600 cites W2038237353 @default.
• W2095482600 cites W2038588513 @default.
• W2095482600 cites W2038764487 @default.
• W2095482600 cites W2044523049 @default.
• W2095482600 cites W2050486755 @default.
• W2095482600 cites W2053706041 @default.
• W2095482600 cites W2059335277 @default.
• W2095482600 cites W2066147217 @default.
• W2095482600 cites W2071396208 @default.
• W2095482600 cites W2073757477 @default.
• W2095482600 cites W2076420398 @default.
• W2095482600 cites W2076860432 @default.
• W2095482600 cites W2079373334 @default.
• W2095482600 cites W2079846837 @default.
• W2095482600 cites W2081753155 @default.
• W2095482600 cites W2084714565 @default.
• W2095482600 cites W2091046463 @default.
• W2095482600 cites W2092634513 @default.
• W2095482600 cites W2095561478 @default.
• W2095482600 cites W2102960042 @default.
• W2095482600 cites W2104522700 @default.
• W2095482600 cites W2104844996 @default.
• W2095482600 cites W2114307396 @default.
• W2095482600 cites W2117967389 @default.
• W2095482600 cites W2118658156 @default.
• W2095482600 cites W2119226169 @default.
• W2095482600 cites W2125677685 @default.
• W2095482600 cites W2129974957 @default.
• W2095482600 cites W2133101492 @default.
• W2095482600 cites W2142038792 @default.
• W2095482600 cites W2143394172 @default.
• W2095482600 cites W2152864559 @default.
• W2095482600 cites W2152965325 @default.
• W2095482600 cites W2154435473 @default.
• W2095482600 cites W2157602863 @default.
• W2095482600 cites W2158385759 @default.
• W2095482600 cites W2159873817 @default.
• W2095482600 cites W2162700884 @default.
• W2095482600 cites W2795831496 @default.
• W2095482600 cites W285884537 @default.
• W2095482600 cites W60245997 @default.
• W2095482600 cites W745796678 @default.
• W2095482600 doi "https://doi.org/10.2147/ndt.s16085" @default.
• W2095482600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3261649" @default.
• W2095482600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22275842" @default.
• W2095482600 hasPublicationYear "2011" @default.
• W2095482600 type Work @default.
• W2095482600 sameAs 2095482600 @default.
• W2095482600 citedByCount "4" @default.
• W2095482600 countsByYear W20954826002012 @default.
• W2095482600 countsByYear W20954826002013 @default.
• W2095482600 countsByYear W20954826002018 @default.

• next